Detail page

Knowledge Web

Person

Hartmut Döhner (1957-)

Hämatologe

Name	Hartmut Döhner
Time	1957- (Date of birth and death)
Place	Deutschland
Academic degree	Prof. Dr.
Profession	Hämatologe (characteristic profession)
Variant	Hartmut Doehner H. Döhner
Related	Medizinische Universitäts-Poliklinik (Heidelberg) (1993-1999) Universitätsklinikum Ulm Internistische Onkologie (Thema)
Source	Homepage: https://www.uniklinik-ulm.de/fileadmin/default/Kliniken/Innere_Medizin_3/Team/Z-Doehner_CV_English_Homepage_Jan_2022.pdf (Stand: 24.03.2022)
Record type	Person
GND-Identifier	110666585
Record ID	110666585
Involved in show all Rearrangements involving 11q23.3/KMT2A in adult AML: mutational landscape and prognostic implications – a HARMONY study The proteogenomic landscape of multiple myeloma reveals insights into disease biology and therapeutic opportunities Correction: Clinical impact of the genomic landscape and leukemogenic trajectories in non-intensively treated elderly acute myeloid leukemia patients Clinical impact of the genomic landscape and leukemogenic trajectories in non-intensively treated elderly acute myeloid leukemia patients AML consolidation therapy: timing matters Clinicohematologic and molecular response of essential thrombocythemia patients treated with pegylated interferon-α : a multi-center study of the German Study Group-Myeloproliferative Neoplasms (GSG-MPN) Clinicohematologic and molecular response of essential thrombocythemia patients treated with pegylated interferon-α : a multi-center study of the German Study Group-Myeloproliferative Neoplasms (GSG-MPN) In vivo kinetics of early, non-random methylome and transcriptome changes induced by DNA-hypomethylating treatment in primary AML blasts In vivo kinetics of early, non-random methylome and transcriptome changes induced by DNA-hypomethylating treatment in primary AML blasts Palbociclib in acute leukemias with KMT2A-rearrangement: results of AMLSG 23-14 trial Cancer care in German centers of excellence during the first 2 years of the COVID-19 pandemic Unified classification and risk-stratification in Acute Myeloid Leukemia Cancer care in German centers of excellence during the first 2 years of the COVID-19 pandemic Midostaurin plus intensive chemotherapy for younger and older Patients with AML and FLT3 internal tandem duplications P448: Prognostic impact of somatic CEBPA BZIP domain mutations in acute myeloid leukemia P768: Guadecitabine (SGI-110) vs. treatment choice (TC) in relapsed/refractory(R/R) myelodysplastic syndrome (MDS), results of a global, randomized, phase 3 study P1055: Clinical and genetic results of the phase IB/II TRIAL MPNSG-0212: ruxolitinib plus pomalidomide in myelofibrosis with anemia Molecular landscape and prognostic impact of FLT3-ITD insertion site in acute myeloid leukemia: RATIFY study results Venetoclax - ein neuer Therapiestandard in der AML Monosomal karyotype and chromosome 17p loss or TP53 mutations in decitabine-treated patients with acute myeloid leukemia Gemtuzumab ozogamicin in NPM1-mutated acute myeloid leukemia: early results from the prospective randomized AMLSG 09-09 Phase III Study Monosomal karyotype and chromosome 17p loss or TP53 mutations in decitabine-treated patients with acute myeloid leukemia Randomized phase-II trial evaluating induction therapy with idarubicin and etoposide plus sequential or concurrent azacitidine and maintenance therapy with azacitidine KIT D816 mutated/CBF-negative acute myeloid leukemia: a poor-risk subtype associated with systemic mastocytosis KIT D816 mutated/CBF-negative acute myeloid leukemia: a poor-risk subtype associated with systemic mastocytosis Adding dasatinib to intensive treatment in core-binding factor acute myeloid leukemia—results of the AMLSG 11-08 trial Midostaurin : Multi-Target-Kinase-Hemmer Azacitidine improves clinical outcomes in older patients with acute myeloid leukaemia with myelodysplasia-related changes compared with conventional care regimens Epidemiological, genetic, and clinical characterization by age of newly diagnosed acute myeloid leukemia based on an academic population-based registry study (AMLSG BiO) Epidemiological, genetic, and clinical characterization by age of newly diagnosed acute myeloid leukemia based on an academic population-based registry study (AMLSG BiO) Impact of pretreatment characteristics and salvage strategy on outcome in patients with relapsed acute myeloid leukemia Epigenetic upregulation of lncRNAs at 13q14.3 in leukemia is linked to the in cis downregulation of a gene cluster that targets NF-kB Molecular Diagnostics in Hematological Oncology Molecular cytogenetic analysis of B-cell chronic lymphocytic leukemia Fluoreszenz-in-situ-Hybridisierung (FISH) : Methodik und Anwendung Molekularzytogenetische Analyse chronisch lymphatischer Leukämien Nifedipin und Aprotinin zur Kardioplegie und Myokardprotektion : e. hämodynam. u. ultrastrukturell-morphometr. Unters.

Please note

The beta version does not yet contain all functions and information of the DNB portal catalogue. If you are missing information or want to order a medium, please visit the page in the DNB portal catalogue via the following link:

Katalog der Deutschen Nationalbibliothek

Hartmut Döhner (1957-)

Rearrangements involving 11q23.3/KMT2A in adult AML: mutational landscape and prognostic implications – a HARMONY study

The proteogenomic landscape of multiple myeloma reveals insights into disease biology and therapeutic opportunities

Correction: Clinical impact of the genomic landscape and leukemogenic trajectories in non-intensively treated elderly acute myeloid leukemia patients

Clinical impact of the genomic landscape and leukemogenic trajectories in non-intensively treated elderly acute myeloid leukemia patients

AML consolidation therapy: timing matters

Clinicohematologic and molecular response of essential thrombocythemia patients treated with pegylated interferon-α : a multi-center study of the German Study Group-Myeloproliferative Neoplasms (GSG-MPN)

Clinicohematologic and molecular response of essential thrombocythemia patients treated with pegylated interferon-α : a multi-center study of the German Study Group-Myeloproliferative Neoplasms (GSG-MPN)

In vivo kinetics of early, non-random methylome and transcriptome changes induced by DNA-hypomethylating treatment in primary AML blasts

In vivo kinetics of early, non-random methylome and transcriptome changes induced by DNA-hypomethylating treatment in primary AML blasts

Palbociclib in acute leukemias with KMT2A-rearrangement: results of AMLSG 23-14 trial

Cancer care in German centers of excellence during the first 2 years of the COVID-19 pandemic

Unified classification and risk-stratification in Acute Myeloid Leukemia

Cancer care in German centers of excellence during the first 2 years of the COVID-19 pandemic

Midostaurin plus intensive chemotherapy for younger and older Patients with AML and FLT3 internal tandem duplications

P448: Prognostic impact of somatic CEBPA BZIP domain mutations in acute myeloid leukemia

P768: Guadecitabine (SGI-110) vs. treatment choice (TC) in relapsed/refractory(R/R) myelodysplastic syndrome (MDS), results of a global, randomized, phase 3 study

P1055: Clinical and genetic results of the phase IB/II TRIAL MPNSG-0212: ruxolitinib plus pomalidomide in myelofibrosis with anemia

Molecular landscape and prognostic impact of FLT3-ITD insertion site in acute myeloid leukemia: RATIFY study results

Venetoclax - ein neuer Therapiestandard in der AML

Monosomal karyotype and chromosome 17p loss or TP53 mutations in decitabine-treated patients with acute myeloid leukemia

Gemtuzumab ozogamicin in NPM1-mutated acute myeloid leukemia: early results from the prospective randomized AMLSG 09-09 Phase III Study

Monosomal karyotype and chromosome 17p loss or TP53 mutations in decitabine-treated patients with acute myeloid leukemia

Randomized phase-II trial evaluating induction therapy with idarubicin and etoposide plus sequential or concurrent azacitidine and maintenance therapy with azacitidine

KIT D816 mutated/CBF-negative acute myeloid leukemia: a poor-risk subtype associated with systemic mastocytosis

KIT D816 mutated/CBF-negative acute myeloid leukemia: a poor-risk subtype associated with systemic mastocytosis

Adding dasatinib to intensive treatment in core-binding factor acute myeloid leukemia—results of the AMLSG 11-08 trial

Midostaurin : Multi-Target-Kinase-Hemmer

Azacitidine improves clinical outcomes in older patients with acute myeloid leukaemia with myelodysplasia-related changes compared with conventional care regimens

Epidemiological, genetic, and clinical characterization by age of newly diagnosed acute myeloid leukemia based on an academic population-based registry study (AMLSG BiO)

Epidemiological, genetic, and clinical characterization by age of newly diagnosed acute myeloid leukemia based on an academic population-based registry study (AMLSG BiO)

Impact of pretreatment characteristics and salvage strategy on outcome in patients with relapsed acute myeloid leukemia

Epigenetic upregulation of lncRNAs at 13q14.3 in leukemia is linked to the in cis downregulation of a gene cluster that targets NF-kB

Molecular Diagnostics in Hematological Oncology

Molecular cytogenetic analysis of B-cell chronic lymphocytic leukemia

Fluoreszenz-in-situ-Hybridisierung (FISH) : Methodik und Anwendung

Molekularzytogenetische Analyse chronisch lymphatischer Leukämien

Nifedipin und Aprotinin zur Kardioplegie und Myokardprotektion : e. hämodynam. u. ultrastrukturell-morphometr. Unters.